GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36508
Submission : 2022-06-16
Status : Active
Type : IV
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 36508
Submission : 2022-06-16
Status : Active
Type : IV
FINISHED DOSAGE FORMULATIONS
Drug : PRIMAQUINE
Dosage Form : TABLET; ORAL
Application Number : 8316
Country : US
Patented : No
Drug : KALETRA
Dosage Form : TABLET; ORAL
Application Number : 21906
Country : US
Patented : No
Drug : NAMENDA
Dosage Form : TABLET; ORAL
Application Number : 21487
Country : US
Patented : No
Drug : NAMENDA XR
Dosage Form : CAPSULE, EXTENDED RELEASE; ORAL
Application Number : 22525
Country : US
Patented : Yes
Drug : NORVIR
Dosage Form : TABLET; ORAL
Application Number : 22417
Country : US
Patented : No
ESTROGENS, CONJUGATED SYNTHETIC B
Drug : ENJUVIA
Dosage Form : TABLET; ORAL
Application Number : 21443
Country : US
Patented : No
Drug : CLOPIDOGREL BISULFATE
Dosage Form : TABLET; ORAL
Application Number : 76273
Country : US
Patented : No
ESOMEPRAZOLE MAGNESIUM; NAPROXEN
Drug : NAPROXEN AND ESOMEPRAZOLE MAGNESIUM
Dosage Form : TABLET, DELAYED RELEASE; ORAL
Application Number : 204206
Country : US
Patented : No
Drug : TAMOXIFEN CITRATE
Dosage Form : TABLET; ORAL
Application Number : 75797
Country : US
Patented : No
EXCIPIENTS BY APPLICATIONS
Application : Rheology Modifiers
Excipient Details : Polyglykol 400 is a liquid PEG excipient grade product which is used as solvent, humectant, coating agent and viscosity enhancer.
Pharmacopoeia Ref : USP-NF: Polyethylene glycol 40...
Technical Specs : average molar mass 400 g/mol
Ingredient(s) : Polyethylene Glycol 400
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Topical, Oral
Category : Surfactant & Foaming Agents
MARKET PLACE
Reply
22 Mar 2025
Reply
31 Jul 2024